Trials / Completed
CompletedNCT01178346
Pharmacoeconomic Assessment in Nabi-4514 and Nabi-4515 Phase 3 Studies
Health-Related Quality-of-Life and Health-Care Resource Utilization Assessment in Nabi-4514 and Nabi-4515 Phase 3 Studies
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 500 (actual)
- Sponsor
- Nabi Biopharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to look at pharmacoeconomic data for subjects that have received either NicVAX or placebo in the Nabi-4514 or Nabi-4515 studies.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | NicVAX vaccine | NicVAX vaccine given 6 times over 6 months |
| BIOLOGICAL | Placebo | Placebo vaccine given 6 times over 6 months |
Timeline
- Start date
- 2010-07-01
- Primary completion
- 2011-11-01
- Completion
- 2011-11-01
- First posted
- 2010-08-10
- Last updated
- 2012-05-09
Locations
25 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01178346. Inclusion in this directory is not an endorsement.